TY - JOUR
T1 - Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin i and incident atrial fibrillation
AU - Rienstra, Michiel
AU - Yin, Xiaoyan
AU - Larson, Martin G.
AU - Fontes, João D.
AU - Magnani, Jared W.
AU - McManus, David D.
AU - McCabe, Elizabeth L.
AU - Coglianese, Erin E.
AU - Amponsah, Michael
AU - Ho, Jennifer E.
AU - Januzzi, James L.
AU - Wollert, Kai C.
AU - Fradley, Michael G.
AU - Vasan, Ramachandran S.
AU - Ellinor, Patrick T.
AU - Wang, Thomas J.
AU - Benjamin, Emelia J.
N1 - Funding Information:
The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents. The Framingham Heart Study is supported by the National Heart, Lung and Blood Institute (contract NO1-HC-25195).
Funding Information:
The Framingham Heart Study is supported by N01-HC 25195. Dr Rienstra is supported by a grant from the Netherlands Organization for Scientific Research (Veni Grant No. 016.136.055 ). This work was supported by grants from the National Institutes of Health to Drs Benjamin and Ellinor ( 1R01HL092577 ), Dr Benjamin ( 1RC1HL101056 , 1R01HL102214 , and support via 6R01-NS 17950), and Dr Ellinor ( 5RO1HL104156 , 1K24HL105780 ). Dr Ellinor is supported by an Established Investigator Award from the American Heart Association (13EIA14220013). Salary support for Dr McManus was provided by National Institutes of Health Grant Nos. 1U01HL105268-01 and KL2RR031981. Dr Magnani is supported by American Heart Association award (09FTF 2190028). Dr Ho is supported by 1K23HL116780. Dr Januzzi is supported, in part, by the Desanctis Clinical Scholar Endowment. Soluble ST2 assays were provided by Critical Diagnostics Inc; hsTnI assays were provided by Singulex, Inc; and GDF-15 assays were provided by Roche Diagnostics, Inc. These companies did not have access to study data and had no input into the data analyses, interpretation, or preparation of the manuscript for submission.
Funding Information:
Dr Januzzi reports receiving grant support from Roche Diagnostics, Critical Diagnostics, Singulex, BG Medicine, Siemens, and Thermo-Fisher.
PY - 2014/1
Y1 - 2014/1
N2 - Background We investigated whether circulating concentrations of soluble ST2, growth differentiation factor-15 (GDF-15), and high-sensitivity troponin I (hsTnI) are associated with incident atrial fibrillation (AF) and whether these biomarkers improve current risk prediction models including AF risk factors, B-type natriuretic peptide (BNP), and C-reactive protein (CRP). Methods We studied the relation between soluble ST2, GDF-15, and hsTnI and development of AF in Framingham Heart Study participants without prevalent AF. We used Cox proportional hazard regression analysis to examine the relation of incident AF during a 10-year follow-up period with each biomarker. We adjusted for standard AF clinical risk factors, BNP, and CRP. Results The mean age of the 3,217 participants was 59 ± 10 years, and 54% were women. During a 10-year follow-up, 242 participants developed AF. In age- and sex-adjusted models, GDF-15 and hsTnI were associated with risk of incident AF; however, after including the AF risk factors and BNP and CRP, only hsTnI was significantly associated with AF (hazard ratio per 1 SD of loge hsTnI, 1.12, 95% CI 1.00-1.26, P =.045). The c statistic of the base model including AF risk factors, BNP, and CRP was 0.803 (95% CI 0.777-0.830) and did not improve by adding individual or all 3 biomarkers. None of the discrimination and reclassification statistics were significant compared with the base model. Conclusion In a community-based cohort, circulating hsTnI concentrations were associated with incident AF. None of the novel biomarkers evaluated improved AF risk discrimination or reclassification beyond standard clinical AF risk factors and biomarkers.
AB - Background We investigated whether circulating concentrations of soluble ST2, growth differentiation factor-15 (GDF-15), and high-sensitivity troponin I (hsTnI) are associated with incident atrial fibrillation (AF) and whether these biomarkers improve current risk prediction models including AF risk factors, B-type natriuretic peptide (BNP), and C-reactive protein (CRP). Methods We studied the relation between soluble ST2, GDF-15, and hsTnI and development of AF in Framingham Heart Study participants without prevalent AF. We used Cox proportional hazard regression analysis to examine the relation of incident AF during a 10-year follow-up period with each biomarker. We adjusted for standard AF clinical risk factors, BNP, and CRP. Results The mean age of the 3,217 participants was 59 ± 10 years, and 54% were women. During a 10-year follow-up, 242 participants developed AF. In age- and sex-adjusted models, GDF-15 and hsTnI were associated with risk of incident AF; however, after including the AF risk factors and BNP and CRP, only hsTnI was significantly associated with AF (hazard ratio per 1 SD of loge hsTnI, 1.12, 95% CI 1.00-1.26, P =.045). The c statistic of the base model including AF risk factors, BNP, and CRP was 0.803 (95% CI 0.777-0.830) and did not improve by adding individual or all 3 biomarkers. None of the discrimination and reclassification statistics were significant compared with the base model. Conclusion In a community-based cohort, circulating hsTnI concentrations were associated with incident AF. None of the novel biomarkers evaluated improved AF risk discrimination or reclassification beyond standard clinical AF risk factors and biomarkers.
UR - http://www.scopus.com/inward/record.url?scp=84890117718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890117718&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2013.10.003
DO - 10.1016/j.ahj.2013.10.003
M3 - Article
C2 - 24332149
AN - SCOPUS:84890117718
SN - 0002-8703
VL - 167
SP - 109-115.e2
JO - American heart journal
JF - American heart journal
IS - 1
ER -